Nicotine - Celltech Group

Drug Profile

Nicotine - Celltech Group

Alternative Names: Nicotine tartrate

Latest Information Update: 29 Mar 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mayo Clinic
  • Developer Celltech Group; Mayo Clinic
  • Class Alkaloids; Analgesics; Drug withdrawal therapies; Nicotine replacement therapy; Pyridines; Small molecules
  • Mechanism of Action Nicotinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Ulcerative colitis

Most Recent Events

  • 29 Mar 2000 Discontinued-Clinical for Ulcerative colitis in USA (PO)
  • 29 Mar 2000 Discontinued-II for Ulcerative colitis in USA (Rectal)
  • 02 Feb 2000 Medeva has been merged into Celltech Chiroscience, which is now called Celltech Group
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top